Results 221 to 230 of about 82,196 (246)
Some of the next articles are maybe not open access.
Prescribing the Buprenorphine Monoproduct for Adverse Effects of Buprenorphine-Naloxone
Journal of Addiction Medicine, 2021Buprenorphine-naloxone (BNX) reduces the risk of mortality from untreated opioid use disorder by 50% or more. However, adverse effects of BNX can be a cause of inconsistent use or discontinuation. The buprenorphine monoproduct (BUP) is effective and is sometimes tolerated better, but practice guidelines and insurance ...
openaire +3 more sources
Journal of Opioid Management, 2018
A significant breakthrough in the treatment of opioid addiction occurred with the passage of the Data Addiction Treatment Act of 2000 (DATA 2000),1 signed into law by President Clinton, which allowed physicians for the first time in more than eight decades to prescribe opioid medications for the treatment of opioid addiction in the normal course of ...
openaire +3 more sources
A significant breakthrough in the treatment of opioid addiction occurred with the passage of the Data Addiction Treatment Act of 2000 (DATA 2000),1 signed into law by President Clinton, which allowed physicians for the first time in more than eight decades to prescribe opioid medications for the treatment of opioid addiction in the normal course of ...
openaire +3 more sources
Effect of buprenorphine on psychomotor functions in patients on buprenorphine maintenance
Journal of Opioid Management, 2018Objective: Patients on buprenorphine maintenance for opioid dependence often abuse its additional doses over and above the maintenance dose. Being a psychoactive agent, it may affect psychomotor performance with all its consequences, for example, effect on quality of life.
Raka Jain, MSc, PhD, Cchem, Frsc +4 more
openaire +3 more sources
Behavioral pharmacology of buprenorphine
Drug and Alcohol Dependence, 1985Buprenorphine is an opioid mixed agonist-antagonist that has potential usefulness as a pharmacotherapy for opiate addiction. Buprenorphine significantly suppressed opiate self-administration by heroin addicts. Buprenorphine also suppressed opiate self-administration in a primate model.
Nancy K. Mello, Jack H. Mendelson
openaire +3 more sources
Enzyme immunoassay of buprenorphine
Naunyn-Schmiedeberg's Archives of Pharmacology, 1988Assays for the potent, highly lipophilic analgesic buprenorphine described in the literature include the radioimmunoassay (RIA), radioreceptor assay (RRA) and selected ion-monitoring. Problems arise with the use of hazardous and unstable ligand in the RIA and RRA and the need for an extraction step for RRA and selected ion-monitoring.
Jean E. Olley, George K. L. Tiong
openaire +3 more sources
Medical Journal of Australia, 1984
Buprenorphine is a powerful new analgesic agent with agonist and antagonist opiate receptor activity. Its withdrawal symptoms have been reported as being mild; however, its potential for abuse is not known. A case of buprenorphine abuse is reported, in which the patient's history and his response to naloxone suggest that important underlying factors ...
Allan J. Quigley +2 more
openaire +3 more sources
Buprenorphine is a powerful new analgesic agent with agonist and antagonist opiate receptor activity. Its withdrawal symptoms have been reported as being mild; however, its potential for abuse is not known. A case of buprenorphine abuse is reported, in which the patient's history and his response to naloxone suggest that important underlying factors ...
Allan J. Quigley +2 more
openaire +3 more sources
Supportive Care in Cancer, 2005
Buprenorphine is a broad spectrum, highly lipophilic, and long-acting partial mu opioid receptor agonist that is noncross tolerant to other opioids. Buprenorphine can be given by several routes. Metabolism is through CYP3A4 and CYP2C8 and by conjugases.
openaire +3 more sources
Buprenorphine is a broad spectrum, highly lipophilic, and long-acting partial mu opioid receptor agonist that is noncross tolerant to other opioids. Buprenorphine can be given by several routes. Metabolism is through CYP3A4 and CYP2C8 and by conjugases.
openaire +3 more sources
Buprenorphine: Beyond Methadone?
Psychiatric Services, 1991This month's guest authors are affiliated with the substance abuse treatment and treatment research unit of the Connecticut Mental Health Center and the department of psychiatry at Yale University School of Medicine, where Dr. Rosen is instructor and Dr. Kosten is associate professor.
Marc I. Rosen, Thomas R. Kosten
openaire +3 more sources
Anesthesia for Patients on Buprenorphine
Anesthesiology Clinics, 2010Opioid abuse is a devastating, costly, and growing problem in the United States, and one for which treatment can be complicated by barriers such as access to care and legal issues. Only 12% to 15% of the opioid-dependent population is enrolled in methadone maintenance programs.
Clifford Gevirtz +2 more
openaire +3 more sources
Buprenorphine for Chronic Pain
Journal of Pain & Palliative Care Pharmacotherapy, 2013Questions from patients about pain conditions, analgesic pharmacotherapy and responses from authors are presented to help educate patients and make them more effective self-advocates. The use of transdermal buprenorphine for chronic pain management is discussed. A brief history of the medication is provided.
Raul Calderon, David J Copenhaver
openaire +3 more sources